gemcitabine / Generic mfg. - LARVOL DELTA

Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study. (PubMed, Lancet Haematol) - P3 | "Although the pre-specified primary outcome of the trial was not met, the favourable safety profile suggests that azacitidine could add to the treatment options in these difficult to treat diseases especially in combination with other drugs. Trials with combination are in preparation in a platform trial."

Clinical • IO biomarker • Journal • P3 data • P3 data • Candidiasis • Cardiovascular • Congestive Heart Failure • Follicular Lymphoma • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • T Cell Non-Hodgkin Lymphoma • BCL6 • CXCL13 • ICOS • MME • PD-1

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. (PubMed, Lancet) - P3 | "Glofit-GemOx had a significant overall survival benefit compared with R-GemOx, supporting its use in transplant-ineligible patients with relapsed or refractory diffuse large B-cell lymphoma after one or more previous lines of therapy."

Clinical • Journal • P3 data • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial. (PubMed, Blood) - P1/2 | "Gemcitabine + oxaliplatin (GemOx) with rituximab, a standard salvage therapy, yields complete response (CR) rates of approximately 30% and median overall survival (OS) of 10-13 months. Epcoritamab + GemOx yielded deep, durable responses and favorable long-term outcomes in ASCT‑ineligible R/R DLBCL. NCT04663347."

Journal • B Cell Lymphoma • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

POLATUZUMAB VEDOTIN, RITUXIMAB, GEMCITABINE AND OXALIPLATIN (POLA-R-GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS FROM THE RANDOMIZED PHASE III POLARGO TRIAL (EHA 2025) - P3 | "Background: Polatuzumab vedotin is approved in frontline and R/R DLBCL, with the latter involving a combination with bendamustine and rituximab (Tilly H, et al. This study met its primary and all key secondary endpoints. Pola-R-GemOx demonstrated a statistically significant and clinically meaningful benefit in OS and PFS, with a 40% reduction in risk of death relative to R-GemOx. Pola-R-GemOx was associated with known risks of individual components, including PN and infection, but neither significantly impacted study endpoints."

Clinical • P3 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain • Thrombocytopenia

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial. (PubMed, J Clin Oncol) - P3 | "Mosun-Pola demonstrated superior efficacy verus R-GemOx, with significant improvements in both overall response rate and progression-free survival, and infrequent cytokine release syndrome events with a manageable safety profile.(Funded by F. Hoffmann-La Roche Ltd; ClinicalTrials.gov, NCT05171647)."

Journal • P3 data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study. (ASCO-GU 2026) - P3 | " Pts with clinical stage T2-T4aN0M0 or T1-T4aN1M0 MIBC (confirmed by central pathology and central imaging assessment) who were eligible for cisplatin-based chemotherapy and RC + PLND were randomized 1:1 to receive either 4 cycles neoadjuvant EV 1.25 mg/kg IV on days 1 and 8 + pembro 200 mg IV on day 1 Q3W, followed by RC + PLND, and adjuvant 5 cycles EV + 13 cycles pembro (EV + pembro arm) vs 4 cycles neoadjuvant gemcitabine 1000 mg/m2 on days 1 and 8 + cisplatin 70 mg/m2 on day 1 Q3W, followed by RC + PLND (cis + gem arm). Neoadjuvant and adjuvant EV + pembro significantly improved EFS, OS, and pCR rate compared with neoadjuvant gem + cis in pts with MIBC who were eligible for cisplatin-based chemotherapy. The safety profile of EV + pembro was consistent with prior experience with the combination. These results support EV + pembro as an effective perioperative treatment option in this setting."

Clinical • Late-breaking abstract • P3 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study (ESMO 2026) - No abstract available

Clinical • P3 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO. (PubMed, Blood Adv) - P3 | "In the phase 3 STARGLO trial (NCT04408638), glofitamab plus gemcitabine-oxaliplatin (Glofit-GemOx) demonstrated superior overall survival (OS) vs rituximab (R)-GemOx, in patients with autologous stem cell transplant (ASCT)-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). With extended follow-up, fixed-duration Glofit-GemOx continues to demonstrate superior survival vs R-GemOx in ASCT-ineligible patients with R/R DLBCL, with favorable outcomes pronounced in the 2L setting, and consistent across subgroups including elderly and early relapsing patients. These data support Glofit-GemOx as an effective off-the-shelf treatment with curative potential in R/R DLBCL."

Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and gallbladder carcinoma (ACTICCA-1 trial) (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Biliary Cancer • Cholangiocarcinoma • Gallbladder Cancer • Oncology • Solid Tumor

Risvutatug Rezetecan (Ris-Rez) versus Gemcitabine and Docetaxel (GD) in Heavily Pretreated Patients (pts) with Relapsed or Refractory (R/R) Osteosarcoma: Primary Results from the Phase 3 ARTEMIS-011 Study (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • P3 data • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Phase 2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guérin (BCG)‒Naïve Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3-Year Outcomes. (PubMed, J Urol) - "Five patients (20%) experienced a grade-3 AE including hematuria and urinary tract infection. The updated 3-year results of this single-arm phase 2 trial suggest continued efficacy and durability of Gem/Doce for this small cohort of BCG-naïve HR NMIBC."

Journal • P2 data • Bladder Cancer • Fatigue • Genito-urinary Cancer • Infectious Disease • Nephrology • Oncology • Pain • Solid Tumor • Urothelial Cancer

18 F-FDG PET/CT for Staging Mycosis Fungoides (EANM 2026) - "Materials and A 65-year-old woman with history of MF treated with Methotrexate and phototherapy, presenting with a newly formed tumoral mass in the right gluteal region...Based on these findings, the disease was classed as T3N1M0B0 and the patient was referred for chemotherapy (Gemcitabine)... PET/CT has shown higher sensitivity and specificity than CT alone in identifying both cutaneous and extracutaneous extension of MF. Thus, improving its diagnostic value for detecting local recurrence and distant metastases. However, its performance remains limited in early-stage disease and in low-metabolic cutaneous lesions."

FDG PET • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Durable Pathological Complete Response After FAP-Targeted Intravesical Lu-177-3BP-3940 Radioligand Therapy in Two Patients with Treatment-Refractory Muscle-Invasive Bladder Cancer (EANM 2026) - "Patient 1 (male, 67 years) had pT2a G3 urothelial carcinoma with progression after three cycles of gemcitabine/cisplatin...Pembrolizumab was initiated but discontinued after two cycles due to immune-related myopathy... This represents the first clinical experience with FAP-targeted iRLT in MIBC. Lu-177-3BP-3940 iRLT showed an excellent safety profile in non-luminal MIBC, achieving intravesical remission in both patients. Although limited by the small sample size and heterogeneous clinical context, these findings support further evaluation of FAP-targeted iRLT as a component of bladder-sparing strategies in molecularly selected MIBC, particularly in KRT5-positive tumors."

Clinical • Bladder Cancer • Gastrointestinal Disorder • Genito-urinary Cancer • Myositis • Oncology • Solid Tumor • Urothelial Cancer • FAP • FGFR3 • HER-2 • KRT20 • KRT5 • NECTIN4

EphA3-directed stromal radioimmunotherapy potentiates chemotherapy and immunotherapy in pancreatic cancer (EANM 2026) - "Combination studies were subsequently performed with gemcitabine or anti-PD-1 in the same tumour model...177Lu-ifabotuzumab showed potent clonogenic inhibition in EphA3-expressing cells, with IC50 of 1.15 MBq/mL in U251 cells and 4.82 MBq/mL in CAF3466 fibroblasts... EphA3-targeted radioimmunotherapy enables selective stromal targeting in pancreatic cancer. Notably, it significantly potentiates standard-of-care treatments, including chemotherapy and immunotherapy, supporting a combination-based therapeutic strategy. The treatments were well tolerated, with reversible haematological toxicity."

IO biomarker • Stroma • Oncology • Pancreatic Cancer • Solid Tumor • EPHA3

Initial Outcomes from the OSPREY Registry of Patients with Unresectable Locally Advanced Pancreatic Cancer Treated with EUS-Guided Phosphorus-32 Microparticles plus Gemcitabine-Based Chemotherapy in Routine Clinical Practice (EANM 2026) - "EUS-guided implantation of 32P-microparticles plus chemotherapy for patients with uLAPC receiving routine clinical care was safe and well tolerated, and appears to provide local disease control, downstaging to surgical resection in a proportion of patients and encouraging survival. Registry enrolment is ongoing and follow-up continues."

Clinical • Metastases • Oncology • Pancreatic Cancer • Pancreatitis • Solid Tumor

Second-Line Systemic Therapy Following First-Line FOLFIRINOX or NALIRIFOX in Metastatic Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. (PubMed, J Gastrointest Cancer) - "This first contemporary synthesis of post-triplet second-line therapy in mPDAC shows meaningful benefit in carefully selected, fit patients. Gemcitabine-based combination therapy is a reasonable option for ECOG 0-1 patients, though treatment should remain individualized based on performance status, toxicity, and preference. These findings provide contemporary benchmarks for practice and future trials."

Clinical • Journal • Retrospective data • Review • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

Patient Characteristics and Treatment Patterns of Advanced Biliary Tract Cancer (BTC): A Chinese Physician Survey. (PubMed, Adv Ther) - P=N/A | "This is the first study to report Chinese physicians' understanding of patient characteristics and treatment patterns for advanced BTC, providing valuable insights which will inform advanced BTC treatment in China."

Journal • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

SEQUENTIAL INTRAVESICAL GEMCITABINE-DOCETAXEL AFTER BCG FAILURE NON-MUSCLE INVASIVE BLADDER CANCER: ONCOLOGICAL OUTCOMES AND SAFETY PROFILE. (PubMed, Fr J Urol) - "Gem/Doce shows promising real-world oncological efficacy with an acceptable safety profile in BCG-failure NMIBC, although optimal surveillance strategies remain to be defined."

Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Metastatic Urachal Carcinoma With Microsatellite Stability and Low Tumor Mutational Burden Achieving a Durable Response to Pembrolizumab After Platinum Failure. (PubMed, IJU Case Rep) - "A 55-year-old woman with metastatic urachal adenocarcinoma progressed after seven cycles of gemcitabine-cisplatin. This case demonstrates durable disease control with pembrolizumab in metastatic urachal carcinoma despite microsatellite stability and low tumor mutational burden. These findings suggest the potential efficacy of pembrolizumab in selected patients with platinum-refractory disease."

IO biomarker • Journal • Tumor mutational burden • Genito-urinary Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI • PD-L1 • TMB

EORTC 2334 - LUMEN (EANO 2026) - "Several systemic therapeutic approaches could be proposed at recurrence, including radionuclide therapy, bevacizumab, the combination of everolimus and sandostatin or chemotherapy like carboplatin, gemcitabine, temozolomide or hydroxyurea. Currently, innovative therapies are under evaluation, including immunotherapies, FAK inhibitors, brigatinib or other targeted therapies."

Brain Cancer • Meningioma • Oncology • Solid Tumor

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) (clinicaltrials.gov) - P1/2 | N=350 | Recruiting | Sponsor: Phanes Therapeutics | N=258 ➔ 350

Checkpoint inhibition • Enrollment change • First-in-human • Monotherapy • Biliary Cancer • Biliary Tract Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • HER-2

BOLSTER: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P2 | N=66 | Completed | Sponsor: Lisata Therapeutics, Inc. | Terminated ➔ Completed

Trial completion • Biliary Cancer • Cholangiocarcinoma • Gallbladder Cancer • Oncology • Solid Tumor

Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis. (PubMed, Clin Genitourin Cancer) - "Biweekly GEMDOC may be a feasible salvage regimen in heavily pretreated mCRPC patients who have exhausted or are ineligible for standard options. Prospective studies are warranted to further investigate these findings."

Journal • Real-world evidence • Retrospective data • Castration-Resistant Prostate Cancer • Febrile Neutropenia • Genito-urinary Cancer • Hematological Disorders • Neutropenia • Oncology • Prostate Cancer • Solid Tumor

Overall and Line-Specific Impact of Targeted Therapies in Advanced Biliary Tract Cancer After Chemoimmunotherapy Failure. (PubMed, J Hepatol) - "Matched targeted therapy was associated with improved outcomes after chemoimmunotherapy failure, particularly when delivered in second line. Early molecular profiling and access to matched agents may reduce missed treatment opportunities."

Journal • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

Biomarker-Directed Sintilimab Monotherapy/combo in Untreated Advanced NSCLC: A Phase II Umbrella Trial (CTONG1702) (IASLC-WCLC 2026) - "This report presents data from seven cohorts: Sintilimab monotherapy: Cohort 14 (PD-L1 TPS ≥ 50%), Cohort 15 (PD-L1 TPS < 50% with TMB-High), Cohort 16 (PD-L1 TPS < 50% with KRAS/TP53 co-mutations); Sintilimab plus platinum-based chemotherapy: Cohort 17 (PD-L1 TPS < 1% non-squamous cell carcinoma, sintilimab + pemetrexed + cisplatin/carboplatin) and Cohort 18 ( PD-L1 TPS < 1% squamous cell carcinoma, sintilimab + gemcitabine + carboplatin); Sintilimab + fruquintinib: Cohort 22 (PD-L1 TPS < 50%) and Cohort 23 (PD-L1 TPS ≥ 50%). The most common adverse events was proteinuria. Conclusions : TMB-High seems to be a good predictor for long PFS and OS of sintilimab monotherapy; Sintilimab combined with fruquintinib showed prolonged PFS and OS, especially in PD-L1 ≥ 50%, suggesting a novel chemo-free regimen worth exploring."

Biomarker • IO biomarker • Metastases • Monotherapy • P2 data • Tumor mutational burden • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Renal Disease • Solid Tumor • Squamous Cell Carcinoma • KRAS • TMB • TP53